Holen Sie sich die Stockscreener-App
15.51
6.74%
0.98
Handel nachbörslich:
15.51
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Reaffirmed as "Buy" by BTIG Research - MarketBeat
Cullinan Therapeutics' stock pullback offers a ... - Pluang
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases - Seeking Alpha
HC Wainwright Has Negative Forecast for CGEM Q1 Earnings - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - uk.finance.yahoo.com
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $35 - Moomoo
510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE - MarketBeat
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 - Yahoo Finance
Cullinan Therapeutics - The Pharma Letter
CGEM Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $33 to $40 - Moomoo
CGEM Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio - Investing News Network
Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances By Investing.com - Investing.com Canada
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - Stocktwits
Cullinan Therapeutics (CGEM) Eyes Key Autoimmune and AML Data Re - GuruFocus
Cullinan delays early-stage data for arthritis drug (CGEX) - Seeking Alpha
Cullinan Therapeutics (CGEM) Shares Drop 7% as CLN-978 Data Rele - GuruFocus
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs - Yahoo Finance
Cullinan Therapeutics (CGEM) Sets Q4 2026 Clinical Updates Amid High Price-to-Sales Valuation - GuruFocus
Cullinan Therapeutics Highlights Fourth Quarter 2026 - GlobeNewswire
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data - Yahoo Finance
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed? - Yahoo Finance
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1%Here's What Happened - MarketBeat
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Investing News Network
Phase III results could broaden opportunity for Cullinan’s lead cancer drug - The Pharma Letter
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Should Phase 3 Lung Cancer Data Require Action From Cullinan Therapeutics (CGEM) Investors? - simplywall.st
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity? - Insider Monkey
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $42 - Moomoo
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $42 - Moomoo
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst CallSlideshow (NASDAQ:CGEM) 2026-09-14 - Seeking Alpha
Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen - Investing.com South Africa
BTIG raises Cullinan Oncology stock price target on trial data - Investing.com
BTIG raises Cullinan Oncology stock price target on trial data By Investing.com - Investing.com Canada
Cullinan Therapeutics: The Market Shrugged At REZILIENT3, But Catalysts Await (CGEM) - Seeking Alpha
Stifel reiterates Cullinan Oncology stock Buy rating on trial data By Investing.com - Investing.com South Africa
Stifel reiterates Cullinan Oncology stock Buy rating on trial data - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results - Yahoo Finance
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):